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Summary
Hyperparathyroidism–jaw tumor syndrome (HPT-JT) is
an autosomal dominant disease characterized by the de-
velopment of multiple parathyroid adenomas and mul-
tiple fibro-osseous tumors of the maxilla and mandible.
Some families have had affected members with involve-
ment of the kidneys, variously reported as Wilms tu-
mors, nephroblastomas, and hamartomas. The HPT-JT
gene (HRPT2) maps to chromosome 1q25–q31. We de-
scribe further investigation of two HPT-JT families
(K3304 and K3349) identified through the literature.
These two expanded families and two previously re-
ported families were investigated jointly for linkage with
21 new, closely linked markers. Multipoint linkage anal-
ysis resulted in a maximum LOD score of 7.83 (at re-
combination fraction 0) for markers D1S2848–D1S191.
Recombination events in these families reduced the
HRPT2 region to ∼14.7 cM. In addition, two of these
four study families (i.e., K3304 and K11687) share a
2.2-cM length of their (expanded) affected haplotype,
indicating a possible common origin. Combining the
linkage data and shared-haplotype data, we propose a
0.7-cM candidate region for HRPT2.
Introduction
Hyperparathyroidism–jaw tumor syndrome (HPT-JT
[MIM 145001]) is an autosomal dominant trait predis-
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posing to the development of parathyroid adenomas and
fibro-osseous jaw tumors (Jackson 1958; Warnakula-
suriya et al. 1985; Jackson et al. 1990; Zarbo et al. 1993;
Inoue et al. 1995) and is distinct from the multiple en-
docrine neoplasia syndromes MEN 1 and MEN 2A
(Jackson et al. 1990; Szabo´ et al. 1995; Hobbs and
Heath 1998). The gene responsible for HPT-JT,HRPT2,
localizes to a 34-cM region on 1q25-q31 (Szabo´ et al.
1995; Teh et al. 1996). We report here the expansion of
two previously reported families (K3304 and K3349)
with HPT-JT (Firat and Stutzman 1968; Kennett and
Pollick 1971; Rosen and Palmer 1981).
Sporadic parathyroid adenomas generally occur at age
140 years, as solitary tumors that do not recur, and are
more common in women than in men (2:1). In HPT-JT,
hypercalcemia has been diagnosed as early as age 10
years (Szabo´ et al. 1995), with 33 years as the mean age
at diagnosis, with men outnumbering women (male:fe-
male ratio 1.6:1) (Fujikawa et al. 1998). Patients become
normocalcemic after removal of these lesions, but para-
thyroid adenomas have recurred many years later (Rosen
and Palmer 1981; Mallette et al. 1987; Jackson et al.
1990). The risk of parathyroid carcinoma is greatly in-
creased in HPT-JT families, now reported in 6 (including
K3304) of 16 HTP-JT families (Dinnen et al. 1977; Kak-
inuma et al. 1994; Fujikawa et al. 1998; Teh et al. 1998).
This is an unusually high prevalence for this rare cancer.
The bone lesions characteristic of HPT-JT are fibro-
osseous tumors of the maxilla and mandible, in contrast
to classical hyperparathyroid osteoclastic “brown tu-
mors,” which may occur elsewhere in the skeleton
(Szabo´ et al. 1995). Sporadic fibro-osseous jaw tumors
of this sort generally occur during the 3d decade of life
or later (Eversole et al. 1985; Slootweg and Muller
1990), being perhaps 2% of all odontogenic tumors (Re-
gezi et al. 1978). In HPT-JT, however, the tumors often
appear in adolescence or young adulthood and are de-
tected in ∼50% of affected individuals (18 of 35 in these
four families) (table 1).
In addition, renal cysts, hamartomas, mesoblastic
nephromas (Teh et al. 1996), or Wilms tumors have been
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Table 1
Frequency of HPT-JT Manifestations
FAMILY
TOTAL NO. (SEX) OF
AFFECTED INDIVIDUALS
NO. (SEX) OF INDIVIDUALS WITH
Hyperparathyroidism
Parathyroid
Cancer Jaw Tumors
Wilms Tumor/
Kidney Cysts
K11687a 12 (7 M, 5 F) 12 (7 M, 5 F) 6 (3 M, 3 F) 1 (0 M, 1 F)
K11690b 7 (5 M, 2 F) 7 (5 M, 2 F) 3 (2 M, 1 F) 1 (0 M, 1 F)
K3304c 8 (5 M, 3 F) 7 (4 M, 3 F) 2 (1 M, 1 F) 5 (3 M, 2 F)
K3349d 8 (2 M, 6 F) 6 (0 M, 6 F) 5 (2 M, 3 F)
Total 35 (19 M, 16 F) 32 (16 M, 16 F) 2 (1 M, 1 F) 19 (10 M, 9 F) 2 (0 M, 2 F)
a Sources: Jackson (1958), Jackson et al. (1990), and Szabo´ et al. (1995).
b Source: Szabo´ et al. (1995).
c Sources: Kennett and Pollick (1971) and Rosen and Palmer (1981).
d Source: Firat and Stutzman (1968).
Figure 1 Pedigree for HPT-JT family 3304. Individuals II-3 and II-7 were originally reported as cases IV and V, respectively, by Rosen
and Palmer (1981). Individuals III-21 and III-15 were originally reported as cases 1 and 2, respectively, by Kennett and Pollick (1971).
reported in six HPT-JT families (Kakinuma et al. 1994;
Szabo´ et al. 1995; Teh et al. 1996). Sporadic and in-
herited Wilms tumors generally occur at age !5 years
(Matsunaga 1981; Huff and Saunders 1993) but, in
HPT-JT, have occurred as late as age 53 years (Kakinuma
et al. 1994).
We have analyzed 21 new polymorphic repeat mark-
ers in four study families, the two expanded families
reported here (K3304 and K3349) and the two most
informative families from our previous study (K11687
and K11690) (Szabo´ et al. 1995). Recombination events
in these families further refine the HRPT2 region to
∼14.7 cM. Haplotype analysis in the affected families
identified a 2.2-cM region of shared alleles within fam-
ilies 3304 and 11687 (Szabo´ et al. 1995). Significantly,
the recombination data and the shared-haplotype data,
when taken together, suggest a 0.7-cM candidate region
for HRPT2.
Patients and Methods
Patients
Kennett and Pollick (1971) and Rosen and Palmer
(1981) reported cases of ossifying fibroma accompanied
by primary hyperparathyroidism, in two separate fam-
ilies from Canada. Investigating these reports, we dis-
covered that they represented two branches of one fam-
ily, K3304 (fig. 1) (Pidwirny et al. 1995). Reinvestigation
of another family, K3349 (fig. 2), originally reported by
Firat and Stutzman (1968), disclosed further affected
individuals in a later generation. Families 11687 and
11690 have been described elsewhere (Szabo´ et al.
1995). A parathyroid adenoma has since been diagnosed
in individual III-4 in family 11690, which we have re-
ported elsewhere (Szabo´ et al. 1995), and thus should
be reclassified as affected.
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Figure 2 Pedigree for HPT-JT family 3349. Individuals II-2 and III-5 were originally reported as cases 2 and 3, respectively, by Firat and
Stutzman (1968).
Informed consent was obtained from all study partic-
ipants. Blood and serum samples were obtained from
each family member, to measure serum calcium levels
and to prepare high-molecular-weight DNA for geno-
typing. Family members were classified as affected if they
had a history of one or more of the following disease
manifestations: elevated serum calcium levels indicative
of hyperparathyroidism, parathyroid adenomas at sur-
gery, fibro-osseous jaw tumors, and/or renal cystic le-
sions or hamartomas; they were classified as unaffected
if their calcium levels were normal (as measured at the
time of blood collection for DNA isolation) and they
had no history of these manifestations. Those who were
either too young to have manifested disease or not avail-
able for testing were classified as unknown.
Family 3304.—Individual II-3 was originally reported
as case IV, and individual II-7 as case V, by Rosen and
Palmer (1981). Individual III-21 was originally reported
as case 1, and individual III-15 as case 2, by Kennett
and Pollick (1971). Serum calcium levels in affected fam-
ily members were 11.5–15.5 mg/dl (normal !10.2 mg/
dl). Affected women were diagnosed at age 14–15 years,
whereas affected males were diagnosed at age 20–40
years. Patients II-3 and III-15 developed parathyroid car-
cinoma; the carcinoma was metastatic in patient III-15,
with a markedly elevated serum parathyroid hormone
level (2,060 ng/liter; normal, !65 ng/liter). Family mem-
bers with jaw tumors underwent two to eight jaw re-
sections for removal of recurrent jaw tumors.
No clinical information is available on patient I-2,
although this individual is obviously an obligate hetero-
zygote. Information on patient II-12 indicates that he
did have jaw tumors.
Family 3349.—Individual II-2 (fig. 2) was originally
reported as case 2, and individual III-5, as case 3, by
Firat and Stutzman (1968). Serum calcium levels in af-
fected family members were 11.3–14.8 mg/dl (normal
!10.2 mg/dl). Affected women were diagnosed at age
21–35 years. Studies of generation II of K3349 are in-
complete; however, patient II-6 had undergone parathy-
roid surgery, and both II-3 and individual II-7 had some
kind of jaw tumor. The HPT-JT lesions of Wilms tumors,
kidney cysts, or kidney hamartomas were not found in
these two families.
DNA Markers
Twenty-one new microsatellite DNA markers in the
HRPT2 region between D1S212 and D1S245 were eval-
uated in the four families studied. The total of 22 mark-
ers (i.e., one previously analyzed marker [D1S191] plus
the 21 new markers) analyzed were (from centromeric
to telomeric) D1S215, D1S2883, D1S2640, D1S2619,
D1S466, D1S2701, CHLC.GATA12F10, D1S240,
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D1S2848, D1S254, D1S444, D1S191, D1S202,
D1S2823, D1S2877, D1S422, D1S412, D1S413,
D1S2853, D1S2622, D1S373, and D1S306. The map
order for these markers was derived from the Ge´ne´thon
map for chromosome 1 (Dib et al. 1996) and from the
chromosome 1 map from the Whitehead Institute for
Biomedical Research/MIT Center for Genome Research.
Allele frequencies used to compute the LOD score were
derived from the unaffected individuals marrying into
the present study’s families that had HPT-JT.
Linkage Analysis
Only the most informative families from our previous
study (i.e., K11687 and K11690) (Szabo´ et al. 1995)
and the two new families (K3304 and K3349) were eval-
uated for this study. Genotyping at each locus by PCR
was performed as described elsewhere (Heath et al.
1993). Data were scored independently by two observ-
ers, and then the results from each were checked against
each other. Linkage calculations were made by FAST-
LINK (Cottingham et al. 1993), version 2.1, modifica-
tions to the LINKAGE software package (Lathrop and
Lalouel 1984). Two-point LOD score analysis was com-
pleted under the assumptions of an autosomal dominant
mode of inheritance with a disease-allele frequency of
.0001 and, as reported elsewhere (Szabo´ et al. 1995), a
penetrance of .90. In this genetic model, simulations in-
dicated that these four families could generate an average
expected LOD score of 4.71 and a theoretical maximum
LOD score of 9.17, if all four had tight linkage to a
disease locus (Ott 1989; Weeks et al. 1990). There is
one living, as yet unaffected obligate heterozygote in our
four study familes, individual II-5 (age 54 years) in
K11690, as noted by Szabo´ et al. (1995).
In addition, the GENEHUNTER program (Kruglyak
et al. 1996) was used to generate a multipoint LOD
score, with information from all 22 DNA markers (mul-
tipoint scores). This analysis assumed the same genetic
model parameters as have been described for the two-
point analysis. GENEHUNTER was able to analyze all
22 DNA markers simultaneously. Information from 16
unaffected subjects was omitted, to allow the families to
fit GENEHUNTER’s size constraints. The simultaneous
analysis of multiple markers maximizes the information
from the DNA markers, ensuring against false-negative
results caused by a marker that is less informative in the
families (Ott 1996).
Results
Two-point LOD scores generated by FASTLINK for
the 22 markers in the region ranged from 1.69 (re-
combination fraction [v] 0), at D1S2701, to 8.52 (v 
) at D1S373. D1S373 is a 15-allele marker with het-0
erozygosity of .904 in the four families. This LOD score
of 8.52 approximates the theoretical maximum score
possible with a marker of this informativeness in these
families. Multipoint GENEHUNTER LOD scores (the
totals for all four families) are presented in figure 3. The
maximum LOD score, 7.83, occurred at markers
D1S2848, D1S254, D1S444, and D1S191. Meiotic re-
combination events occurred in K11690 in individuals
III-2 and III-4, placing HRPT2 centromeric to D1S306
(fig. 4A). Furthermore, a recombination event in K3304,
in individual III-7, placed the gene telomeric to
CHLC.GATA12F10 (fig. 4A). We were unable to deter-
mine whether the breakpoint in K3304 lies centromeric
or telomeric to D1S240, since individual II-7 (the parent
of III-7) is homozygous at that marker. This defines an
interval for HRPT2, between CHLC.GATA12F10 and
D1S306 (∼14.7 cM).
In addition to the meiotic recombinations that helped
narrow the HRPT2 region, we observed a maximum
2.2-cM region of haplotype shared by families K3304
and K11687 (fig. 4B). These two families shared af-
fected-haplotype alleles for six markers: D1S466,
D1S2701, CHLC.GATA12F10, D1S240, D1S2848, and
D1S254. The multipoint LOD score was never !3.8, for
any of these six markers. In view of the allele frequencies
for each of these markers (.06, .74, .18, .50, .11, .06,
respectively), the random population frequency of this
haplotype would be expected to be 1/38,000. This hap-
lotype is not present in either the other two HPT-JT
families reported here or any of 30 individuals who mar-
ried into the HPT-JT families. Significantly, when the
shared-haplotype data are combined with the recom-
bination data from K3304, the suggested candidate
region for HRPT2 is further narrowed, to ∼0.7 cM (fig.
4B).
Discussion
We have narrowed the HRPT2 region, by linkage
analysis in four families, to 14.7 cM. The shared affected
haplotype seen in K3304 and K11687 suggests a possible
common ancestor for these two families. We are cur-
rently conducting a genealogical search to identify any
relatedness of these two families. For a disease as rare
as HPT-JT, it is reasonable to expect that some families
might share a common origin. Significantly, the shared
haplotype and the recombination data together suggest
that the candidate region for HRPT2 is only 0.7 cM.
Intriguing candidate genes in the HRPT2 14.7-cM re-
gion include those for human cysteine-rich protein
(hCRP), regulators of G protein–signaling 2 (RGS2), and
cyclooxygenase-2 (Cox-2). The hCRP 1q31–q32 is a po-
tential signal-transduction protein or transcription reg-
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Figure 3 LOD scores obtained over the entire 21-cM region tested. The maximum LOD score of 7.83 ( ) was obtained at markersv  0
D1S2848, D1S254, D1S444, and D1S191. Because of space constraints, marker D1S444 is not shown on the centimorgan scale. The LOD
scores remain high across the entire linked region of 14.7 cM. The LOD scores sharply decline at CHLC.GATA12F10 (abbreviated as “12F10”
on the centimorgan scale) and D1S306, where recombination events occurred.
ulator (Liebhaber et al. 1990). hCRP is expressed in
many tissues, including the uterus and kidney (M. R.
Hobbs, unpublished data). RGS (Siderovski et al. 1994,
1996) proteins inhibit signaling by heterotrimeric G pro-
teins and are GTP-activating proteins; the parathyroid
gland calcium-sensing–receptor (CaR) protein is of the
G protein-coupled–receptor type. Mutations in CaR
have been shown to give rise to familial benign (hypo-
calciuric) hypercalcemia (Pearce et al. 1995; Heath et al.
1996). Cox-2 is reportedly overexpressed in colorectal
adenomas and adenocarcinomas (Eberhart et al. 1994).
Transgenic Cox-2 / mice show abnormal kidney de-
velopment and infertility in females (Dinchuk et al.
1995). Futhermore, Cox-2 maps near the shared hap-
lotype region, on the basis of the human transcript map
(Schuler et al. 1996).
HPT-JT is a complex disease. The clinical diversity
and long time span during which the various manifes-
tations of HPT-JT occur probably result in its being an
underrecognized clinical syndrome. Patients may see pe-
diatricians, internists, oncologists, endocrinologists,
dentists, gynecologists, and urologists, who may each be
managing only one aspect of the disease. In clinical prac-
tice, the syndromic nature of these disorders may not be
recognized.
HRPT2 may have a significance that extends beyond
the HPT-JT families described here. The elucidation of
HRPT2 may point to new pathways of tumorigenesis
and may lead to a greater understanding of the processes
involved in the initiation and progression of neoplasia
in many tumor types.
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